Phreesia, Inc. (NYSE:PHR) is a healthcare technology company that provides patient intake management solutions. The company aims to streamline the patient intake process, enhancing the overall healthcare experience. Phreesia competes with other healthcare technology firms, striving to offer innovative solutions that improve patient engagement and operational efficiency.
On September 5, 2025, Truist Financial set a price target of $36 for NYSE:PHR, suggesting a potential price increase of about 28% from its current price of $28.13. This optimistic outlook comes despite the stock's recent decline of approximately 9.87%, with a price drop of $3.08. The stock's price fluctuated between $27.77 and $30.43 during the day.
Phreesia reported mixed results for the second quarter, with earnings of 1 cent per share, surpassing market expectations of a 6-cent loss per share. The company's quarterly sales reached $117.3 million, slightly above the anticipated $116.5 million. This performance reflects Phreesia's ability to exceed market expectations, even as its stock price experienced a decline.
CEO and Co-Founder Chaim Indig expressed pride in Phreesia's achievements, noting the company's first-ever net income positive quarter. This milestone, along with the acquisition of AccessOne, positions Phreesia for future growth. Despite these positive developments, Phreesia shares fell by 8.5%, highlighting the market's mixed reaction to the company's progress.
Phreesia has reaffirmed its fiscal year 2026 sales guidance, projecting between $472 million and $482 million, compared to market estimates of $477.1 million. The company's market capitalization stands at approximately $1.67 billion, with a trading volume of 2,671,494 shares. As Phreesia continues to expand its reach and capabilities, it remains a key player in the healthcare technology sector.
